Cd133: a marker of transit amplification rather than stem cell phenotype in the prostate?
Affiliation
Genito-Urinary Cancer Research Group, University of Manchester Paterson Institute for Cancer Research, Manchester, UK. bengrey@doctors.org.ukIssue Date
2009-04
Metadata
Show full item recordCitation
Cd133: a marker of transit amplification rather than stem cell phenotype in the prostate? 2009, 103 (7):856-8 BJU Int.Journal
BJU InternationalDOI
10.1111/j.1464-410X.2008.08250.xPubMed ID
19076138Language
enISSN
1464-410Xae974a485f413a2113503eed53cd6c53
10.1111/j.1464-410X.2008.08250.x
Scopus Count
Related articles
- CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate.
- Authors: Yamamoto H, Masters JR, Dasgupta P, Chandra A, Popert R, Freeman A, Ahmed A
- Issue date: 2012
- Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells.
- Authors: Rentala S, Mangamoori LN
- Issue date: 2010
- Prominin1 (CD133) as an intestinal stem cell marker: promise and nuance.
- Authors: Montgomery RK, Shivdasani RA
- Issue date: 2009 Jun
- Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells.
- Authors: Zhou J, Wang H, Cannon V, Wolcott KM, Song H, Yates C
- Issue date: 2011 Sep 14
- CD133 as a marker for cancer stem cells: progresses and concerns.
- Authors: Wu Y, Wu PY
- Issue date: 2009 Oct